 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 March 1994 | Volume 120 Issue 6 | Pages 476-484
Objective: To determine if polyvalent IgG is promising therapy for severe IgA nephropathy.
Design: Open prospective cohort study.
Setting: Referral nephrology unit.
Patients: 11 adult patients with severe IgA nephropathy (9 who had idiopathic disease and 2 who had Henoch-Schonlein purpura) and indicators of poor prognosis.
Intervention: Patients were given high-dose immunoglobulins (2 g/kg each month) for 3 successive months, followed by intramuscular immunoglobulins (preparation content, 16.5%; 0.35 mL/kg every 15 days) for another 6 months.
Measurements: Histologic changes were analyzed by comparing pre- and post-therapy renal biopsy specimens blindly, using an activity index (14-point scale), a sclerosis index (10-point scale), and a semiquantitative immunofluorescence test of immune deposits. Proteinuria, hematuria, leukocyturia, enzymuria, and global renal function (creatinine and polyfructosan clearances) were evaluated before and after intervention.
Results: Proteinuria (median level before intervention, 5.20 g/d; median level after intervention, 2.25 g/d), hematuria, and leukocyturia decreased substantially. The decrease in glomerular filtration rate was greatly slowed or stopped (median rate of decline in glomerular filtration before, –3.78 mL/min per month; after, 0 mL/min per month). The histologic index of activity (median index before, 5; after, 2) and the staining intensity of glomerular IgA and C3 deposits also decreased. Immunoglobulin therapy was well tolerated.
Conclusions: Immunoglobulin therapy may be effective in treating severe IgA nephropathy and protecting renal function. However, prospective controlled trials must confirm these preliminary results.
Author and Article Information
From Hopital Henri Mondor, Creteil, France.
ARTICLE
High-Dose Immunoglobulin Therapy for Severe IgA Nephropathy and Henoch-Schonlein Purpura
Requests for Reprints: Guy Rostoker, MD, PhD, Service de Nephrologie, Hopital Henri Mondor, 51 Avenue du General De Lattre De Tassigny, 94010 Creteil, France.
Acknowledgments: The authors thank Drs. Gilles Avenard, Francoise Peltier-Pujol, and Clotilde Bremard-Oury for technical assistance.
Grant Support: By INSERM, AURA, Universite Paris XII Val-de-Marne.
This article has been cited by other articles:
|
|
 |
|
  C. Gomez-Guerrero, N. Duque, M. T. Casado, C. Pastor, J. Blanco, F. Mampaso, F. Vivanco, and J. Egido Administration of IgG Fc Fragments Prevents Glomerular Injury in Experimental Immune Complex Nephritis J. Immunol., February 15, 2000; 164(4): 2092 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. RAI, C. NAST, and S. ADLER Henoch-Schonlein Purpura Nephritis J. Am. Soc. Nephrol., December 1, 1999; 10(12): 2637 - 2644. [Full Text]
|
|
|
|
 |
|
 H. Yokoyama, S. Goshima, T. Wada, M. Takaeda, K. Furuichi, K.-i. Kobayashi, H. Kida, and the Kanazawa Study Group for Renal Diseases and Hy The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2379 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Hricik, M. Chung-Park, and J. R. Sedor Glomerulonephritis N. Engl. J. Med., September 24, 1998; 339(13): 888 - 899. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Durand-Zaleski, S. Bastuji-Garin, S. Zaleski, B. Weil, and G. Rostoker A Cost Analysis of the Prevention of End-stage Renal Disease: Immunoglobulin Therapy for IgA Nephropathy Med Decis Making, October 1, 1996; 16(4): 326 - 334. [Abstract] [PDF]
|
|
|
|
|
|
F. A. Sonnenberg Immunoglobulin Therapy for IgA Nephropathy: When Is Cost Saving Enough? Med Decis Making, October 1, 1996; 16(4): 420 - 421. [PDF]
|
|
Article
